- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
別名: Leurocristine sulfate, NSC-67574 sulfate, 22-Oxovincaleukoblastine sulfate 中文名稱:硫酸長春新堿
Vincristine sulfate通過與微管蛋白結合而抑制微管聚合,IC50為32 μM。Vincristine sulfate可誘導凋亡。
Vincristine sulfate Chemical Structure
CAS: 2068-78-2
細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
---|---|---|---|---|---|
H1299/ICAM-3 | Cell Viability Assay | 0-20 nM | 96 h | inhibits cell viability dose dependently | 24177012 |
NCI-H1299/pcDNA3 | Cell Viability Assay | 0-20 nM | 96 h | inhibits cell viability dose dependently | 24177012 |
Ramos | Apoptosis Assay | 2?μM | 48 h | induces 34.6%±1.92% apoptosis | 24256491 |
CCD18Co | Growth Inhibition Assay | 0-1000 nM | 48 h | inhibits cell growth dose dependently | 24403453 |
DLD-1 | Growth Inhibition Assay | 0-1000 nM | 48 h | inhibits cell growth dose dependently | 24403453 |
CCD18Co | Function Assay | 100 nM | 48 h | promotes RUNX3 demethylation? | 24403453 |
DLD-1 | Function Assay | 100 nM | 48 h | promotes RUNX3 demethylation? | 24403453 |
U-251MG | Growth Inhibition Assay | 0.1?μM | 24/72 h | inhibits cell growth time dependently | 24530235 |
A-172? | Growth Inhibition Assay | 0.1?μM | 24/72 h | inhibits cell growth time dependently | 24530235 |
SUDHL6? | Function Assay | 1?μM | 72 h | induces significant apoptotic morphology changes cotrested with BCL11A siRNA | 24961604 |
SUDHL6? | Growth Inhibition Assay | 1?μM | 48/72 h | inhibits cell viability significantly | 24961604 |
P12 | Growth Inhibition Assay | 1-3 nM | 48?h | decreases viable cell numbers dose dependently | 25156146 |
CEM | Growth Inhibition Assay | 1-3 nM | 48?h | decreases viable cell numbers dose dependently | 25156146 |
Jurkat | Growth Inhibition Assay | 1-3 nM | 48?h | decreases viable cell numbers dose dependently | 25156146 |
SK-MEL-28? | Function Assay | 30 nM | 6 h | induces G2–M cell-cycle arrest | 25313010 |
Raji | Function Assay | 0.5?μM | 72 h | abolishes autophagy? | 25446377 |
HepG2-HBV1.1 | Growth Inhibition Assay | 0.1 μM | 12-72 h | induces cell cycle arrest at S-phase | 25663769 |
HepG2-HBV1.1 | Growth Inhibition Assay | 0.1 μM | 12-72 h | induces cell cycle arrest at S-phase | 25663769 |
HepG2-HBV1.1 | Growth Inhibition Assay | 0.1 μM | 1-5 d | inhibits the proliferation time dependently | 25663769 |
HepG2-HBV1.1 | Growth Inhibition Assay | 0.1 μM | 1-5 d | inhibits the proliferation time dependently | 25663769 |
HepG2-HBV1.1 | Function Assay | 0.1 μM | 48 h | promotes cell excretion of hepatitis B virus nucleocapsids instead of hepatitis B virus Dane particles | 25663769 |
HepG2-HBV1.1 | Function Assay | 0.1 μM | 24 h | promotes hepatitis B virus protein expression | 25663769 |
HepG2.2.15 | Function Assay | 0.1 μM | 24 h | promotes hepatitis B virus protein expression | 25663769 |
HepG2-HBV1.1 | Apoptosis Assay | 0-0.5 μM | 24 h | induces apoptosis dose dependently | 25663769 |
HepG2.2.15 | Cell Viability Assay | 0-0.5 μM | 24 h | decreases cell viability dose dependently | 25663769 |
NCI-H1299/pcDNA3 | Function Assay | 1/5/10/20?nM | 96 h | induces cleavage of caspases-3, 8, 9, and PARP | 24177012 |
H1299/ICAM-3 | Function Assay | 1/5/10/20?nM | 96 h | induces cleavage of caspases-3, 8, 9, and PARP | 24177012 |
K562 | Apoptosis Assay | 0.3 μM | 24 h | induces apoptosis significantly | 24135937 |
K562/ADR | Apoptosis Assay | 3 μM | 24 h | induces apoptosis | 24135937 |
K562 | Cell Viability Assay | 3.75–60?nM | 72?h? | inhibits cell viability dose dependently | 23877223 |
lucena | Cell Viability Assay | 3.75–60?nM | 72?h? | no effect | 23877223 |
FEPS | Cell Viability Assay | 3.75–60?nM | 72?h? | no effect | 23877223 |
Jurkat | Apoptosis Assay | 5?μg/ml? | 24 h | induces apoptosis significantly | 23810409 |
Jurkat | Growth Inhibition Assay | 5?μg/ml? | 24 h | arrest Jurkat cells in G2/M phase | 23810409 |
SGC-7901 | Growth Inhibition Assay | 0-10 μg/ml | 24/48/72 h | inhibits cell growth in dose and time dependent manner | 23743572 |
SGC-7901/VCR | Growth Inhibition Assay | 0-10 μg/ml | 24/48/72 h | inhibits cell growth in dose and time dependent manner | 23743572 |
JFCR39? | Growth Inhibition Assay | 1 μM | 24 h | markedly increases the number of G2/M phase cells | 23598276 |
A549 | Function Assay | 100 nM | 16 h | leads to a loss of microtubules | 23598276 |
SH-SY5Y? | Growth Inhibition Assay | 0.001-10 μM | 24 h | IC50=0.113±0.012 μM | 23129065 |
SH-SY5Y? | Growth Inhibition Assay | 0.001-10 μM | 48 h | IC50=0.078±0.009 μM | 23129065 |
SH-SY5Y? | Growth Inhibition Assay | 0.001-10 μM | 72 h | IC50=0.051±0.008 μM | 23129065 |
SH-SY5Y | Apoptosis Assay | 0.1 μM | 0-24 h | induces apoptosis of SH-SY5Y cells following cell cycle arrest at the G2/M phase | 23129065 |
SH-SY5Y | Apoptosis Assay | 0.1 μM | 0-24 h | induces mitotic arrest? | 23129065 |
A549/EGFP? | Growth Inhibition Assay | 0.01-1000 μM | IC50=86.7 ± 29.1 μM | 23634282 | |
A549/Slug | Growth Inhibition Assay | 0.01-1000 μM | IC50=9.7 ± 3.1 μM | 23634282 | |
HepG2 | Growth Inhibition Assay | 24 h | IC50=52.5?μM | 24341688 | |
TCC | Growth Inhibition Assay | 48 h | IC50=50 nM | 24716944 | |
TCC | Growth Inhibition Assay | 24 h | IC50=70 nM | 24716944 | |
LNCAP | Cytotoxicity assay | 72 hrs | Cytotoxicity against human LNCAP cells after 72 hrs by alamar blue assay, IC50 = 0.0029 μM. | 20732809 | |
LNCAP | Cytotoxicity assay | 72 hrs | Cytotoxicity against human LNCAP cells after 72 hrs by alamar blue assay, IC50 = 0.0061 μM. | 23215348 | |
PC3 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay, IC50 = 0.011 μM. | 20732809 | |
PC3 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay, IC50 = 0.015 μM. | 23215348 | |
PC3 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay, IC50 = 0.0153 μM. | 23489291 | |
NFF | Cytotoxicity assay | 72 hrs | Cytotoxicity against human NFF cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay, IC50 = 0.0169 μM. | 23489291 | |
NFF | Cytotoxicity assay | 72 hrs | Cytotoxicity against human NFF cells after 72 hrs by alamar blue assay, IC50 = 0.017 μM. | 23215348 | |
A549 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay, IC50 = 0.02 μM. | 23215348 | |
KB | Cytotoxicity assay | 72 hrs | Cytotoxicity against human KB cells after 72 hrs by SRB assay, IC50 = 0.02 μM. | 26522953 | |
PC3 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay, IC50 = 0.0276 μM. | 28038323 | |
HEK | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HEK cells after 72 hrs by alamar blue assay, IC50 = 0.031 μM. | 23215348 | |
HeLa | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay, IC50 = 0.0358 μM. | 23489291 | |
HeLa | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HeLa cells after 72 hrs by alamar blue assay, IC50 = 0.036 μM. | 23215348 | |
BT549 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human BT549 cells after 48 hrs by MTT assay, IC50 = 0.05472 μM. | 28038323 | |
DU145 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay, IC50 = 0.0723 μM. | 28038323 | |
Leukemia cells | Antitumor assay | 48 hrs | Antitumor activity against human Leukemia cells after 48 hrs by SRB assay, GI50 = 0.1 μM. | 19006285 | |
Leukemia cells | Antitumor assay | 48 hrs | Antitumor activity against human Leukemia cells after 48 hrs by SRB assay, GI = 0.1 μM. | 19006285 | |
Colon cancer cells | Antitumor assay | 48 hrs | Antitumor activity against human Colon cancer cells after 48 hrs by SRB assay, GI50 = 0.1 μM. | 19006285 | |
Colon cancer cells | Antitumor assay | 48 hrs | Antitumor activity against human Colon cancer cells after 48 hrs by SRB assay, GI = 0.1 μM. | 19006285 | |
Leukemia cells | Growth inhibition assay | 48 hrs | Growth inhibition of human leukemia cells after 48 hrs, GI50 = 0.1 μM. | 20684599 | |
Colon cancer cells | Growth inhibition assay | 48 hrs | Growth inhibition of human colon cancer cells after 48 hrs, GI50 = 0.1 μM. | 20684599 | |
Leukemia cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human leukemia cells after 48 hrs, GI50 = 0.1 μM. | 24747749 | |
Colon cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human colon cancer cells after 48 hrs, GI50 = 0.1 μM. | 24747749 | |
Leukemia cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human leukemia cells after 48 hrs, GI50 = 0.1 μM. | 22283430 | |
Colon cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human COLON cells after 48 hrs, GI50 = 0.1 μM. | 22283430 | |
MDA-MB-231 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay, IC50 = 0.1166 μM. | 28038323 | |
CNS | Antitumor assay | 48 hrs | Antitumor activity against human CNS cancer cells after 48 hrs by SRB assay, GI50 = 0.12589 μM. | 19006285 | |
prostate cancer cells | Antitumor assay | 48 hrs | Antitumor activity against human prostate cancer cells after 48 hrs by SRB assay, GI50 = 0.12589 μM. | 19006285 | |
CNS | Antitumor assay | 48 hrs | Antitumor activity against human CNS cancer cells after 48 hrs by SRB assay, GI = 0.13 μM. | 19006285 | |
prostate cancer cells | Antitumor assay | 48 hrs | Antitumor activity against human prostate cancer cells after 48 hrs by SRB assay, GI = 0.13 μM. | 19006285 | |
prostate cancer cells | Growth inhibition assay | 48 hrs | Growth inhibition of human prostate cancer cells after 48 hrs, GI50 = 0.13 μM. | 20684599 | |
CNS | Growth inhibition assay | 48 hrs | Growth inhibition of human CNS cancer cells after 48 hrs, GI50 = 0.13 μM. | 20684599 | |
CNS | Cytotoxicity assay | 48 hrs | Cytotoxicity against human CNS cancer cells after 48 hrs, GI50 = 0.13 μM. | 24747749 | |
prostate cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human prostate cancer cells after 48 hrs, GI50 = 0.13 μM. | 24747749 | |
prostate cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human prostate cancer cells after 48 hrs, GI50 = 0.13 μM. | 22283430 | |
CNS | Cytotoxicity assay | 48 hrs | Cytotoxicity against human CNS cancer cells after 48 hrs, GI50 = 0.13 μM. | 22283430 | |
Melanoma cells | Antitumor assay | 48 hrs | Antitumor activity against human Melanoma cells after 48 hrs by SRB assay, GI50 = 0.15849 μM. | 19006285 | |
Melanoma cells | Antitumor assay | 48 hrs | Antitumor activity against human Melanoma cells after 48 hrs by SRB assay, GI = 0.16 μM. | 19006285 | |
Melanoma cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human melanoma cells after 48 hrs, GI50 = 0.16 μM. | 24747749 | |
Melanoma cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human melanoma cells after 48 hrs, GI50 = 0.16 μM. | 22283430 | |
A549 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human A549 cells after 48 hrs by MTT assay, IC50 = 0.1715 μM. | 28038323 | |
NSCLC | Antitumor assay | 48 hrs | Antitumor activity against human NSCLC cells after 48 hrs by SRB assay, GI = 0.25 μM. | 19006285 | |
NSCLC | Growth inhibition assay | 48 hrs | Growth inhibition of human NSCLC cells after 48 hrs, GI50 = 0.25 μM. | 20684599 | |
NSCLC | Cytotoxicity assay | 48 hrs | Cytotoxicity against human NSCLC cells after 48 hrs, GI50 = 0.25 μM. | 22283430 | |
NSCLC | Cytotoxicity assay | 48 hrs | Cytotoxicity against human NSCLC cells after 48 hrs, GI50 = 0.25 μM. | 24747749 | |
NSCLC | Antitumor assay | 48 hrs | Antitumor activity against human NSCLC cells after 48 hrs by SRB assay, GI50 = 0.25119 μM. | 19006285 | |
ovarian cancer cells | Antitumor assay | 48 hrs | Antitumor activity against human ovarian cancer cells after 48 hrs by SRB assay, GI50 = 0.31623 μM. | 19006285 | |
renal cancer cells | Antitumor assay | 48 hrs | Antitumor activity against human renal cancer cells after 48 hrs by SRB assay, GI50 = 0.31623 μM. | 19006285 | |
breast cancer cells | Antitumor assay | 48 hrs | Antitumor activity against human Breast cancer cells after 48 hrs by SRB assay, GI50 = 0.31623 μM. | 19006285 | |
ovarian cancer cells | Antitumor assay | 48 hrs | Antitumor activity against human ovarian cancer cells after 48 hrs by SRB assay, GI = 0.32 μM. | 19006285 | |
renal cancer cells | Antitumor assay | 48 hrs | Antitumor activity against human renal cancer cells after 48 hrs by SRB assay, GI = 0.32 μM. | 19006285 | |
breast cancer cells | Antitumor assay | 48 hrs | Antitumor activity against human Breast cancer cells after 48 hrs by SRB assay, GI = 0.32 μM. | 19006285 | |
renal cancer cells | Growth inhibition assay | 48 hrs | Growth inhibition of human renal cancer cells after 48 hrs, GI50 = 0.32 μM. | 20684599 | |
breast cancer cells | Growth inhibition assay | 48 hrs | Growth inhibition of human breast cancer cells after 48 hrs, GI50 = 0.32 μM. | 20684599 | |
ovarian cancer cells | Growth inhibition assay | 48 hrs | Growth inhibition of human Ovarian cancer cells after 48 hrs, GI50 = 0.32 μM. | 20684599 | |
breast cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human breast cancer cells after 48 hrs, GI50 = 0.32 μM. | 24747749 | |
renal cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human renal cancer cells after 48 hrs, GI50 = 0.32 μM. | 24747749 | |
ovarian cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human ovarian cancer cells after 48 hrs, GI50 = 0.32 μM. | 24747749 | |
renal cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human renal cancer cells after 48 hrs, GI50 = 0.32 μM. | 22283430 | |
ovarian cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human ovarian cancer cells after 48 hrs, GI50 = 0.32 μM. | 22283430 | |
breast cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human breast cancer cells after 48 hrs, GI50 = 0.32 μM. | 22283430 | |
Lu1 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human Lu1 cells after 72 hrs by SRB assay, IC50 = 0.48 μM. | 26522953 | |
MCF7 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay, IC50 = 0.51 μM. | 26522953 | |
HepG2 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay, IC50 = 0.69 μM. | 26522953 | |
COLON | Growth inhibition assay | 48 hrs | Growth inhibition of human colon cancer cells after 48 hrs, TGI = 3.98 μM. | 20684599 | |
COLON | Cytotoxicity assay | 48 hrs | Cytotoxicity against human colon cancer cells after 48 hrs, TGI = 3.98 μM. | 24747749 | |
COLON | Cytotoxicity assay | 48 hrs | Cytotoxicity against human COLON cells after 48 hrs, TGI = 3.98 μM. | 22283430 | |
COLON | Antitumor assay | 48 hrs | Antitumor activity against human Colon cancer cells after 48 hrs by SRB assay, TGI = 3.98107 μM. | 19006285 | |
CNS | Antitumor assay | 48 hrs | Antitumor activity against human CNS cancer cells after 48 hrs by SRB assay, TGI = 6.30957 μM. | 19006285 | |
prostate cancer cells | Antitumor assay | 48 hrs | Antitumor activity against human prostate cancer cells after 48 hrs by SRB assay, TGI = 6.30957 μM. | 19006285 | |
prostate cancer cells | Growth inhibition assay | 48 hrs | Growth inhibition of human prostate cancer cells after 48 hrs, TGI = 6.31 μM. | 20684599 | |
CNS | Growth inhibition assay | 48 hrs | Growth inhibition of human CNS cancer cells after 48 hrs, TGI = 6.31 μM. | 20684599 | |
CNS | Cytotoxicity assay | 48 hrs | Cytotoxicity against human CNS cancer cells after 48 hrs, TGI = 6.31 μM. | 24747749 | |
prostate cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human prostate cancer cells after 48 hrs, TGI = 6.31 μM. | 24747749 | |
prostate cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human prostate cancer cells after 48 hrs, TGI = 6.31 μM. | 22283430 | |
CNS | Cytotoxicity assay | 48 hrs | Cytotoxicity against human CNS cancer cells after 48 hrs, TGI = 6.31 μM. | 22283430 | |
Melanoma cells | Growth inhibition assay | 48 hrs | Growth inhibition of human melanoma cells after 48 hrs, TGI = 7.94 μM. | 20684599 | |
breast cancer cells | Growth inhibition assay | 48 hrs | Growth inhibition of human breast cancer cells after 48 hrs, TGI = 7.94 μM. | 20684599 | |
breast cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human breast cancer cells after 48 hrs, TGI = 7.94 μM. | 24747749 | |
Melanoma cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human melanoma cells after 48 hrs, TGI = 7.94 μM. | 24747749 | |
Melanoma cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human melanoma cells after 48 hrs, TGI = 7.94 μM. | 22283430 | |
breast cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human breast cancer cells after 48 hrs, TGI = 7.94 μM. | 22283430 | |
Melanoma cells | Antitumor assay | 48 hrs | Antitumor activity against human Melanoma cells after 48 hrs by SRB assay, TGI = 7.94328 μM. | 19006285 | |
breast cancer cells | Antitumor assay | 48 hrs | Antitumor activity against human Breast cancer cells after 48 hrs by SRB assay, TGI = 7.94328 μM. | 19006285 | |
Leukemia cells | Antitumor assay | 48 hrs | Antitumor activity against human Leukemia cells after 48 hrs by SRB assay, TGI = 15.8489 μM. | 19006285 | |
NSCLC | Antitumor assay | 48 hrs | Antitumor activity against human NSCLC cells after 48 hrs by SRB assay, TGI = 15.8489 μM. | 19006285 | |
NSCLC | Growth inhibition assay | 48 hrs | Growth inhibition of human NSCLC cells after 48 hrs, TGI = 15.85 μM. | 20684599 | |
Leukemia cells | Growth inhibition assay | 48 hrs | Growth inhibition of human leukemia cells after 48 hrs, TGI = 15.85 μM. | 20684599 | |
NSCLC | Cytotoxicity assay | 48 hrs | Cytotoxicity against human NSCLC cells after 48 hrs, TGI = 15.85 μM. | 22283430 | |
Leukemia cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human leukemia cells after 48 hrs, TGI = 15.85 μM. | 24747749 | |
NSCLC | Cytotoxicity assay | 48 hrs | Cytotoxicity against human NSCLC cells after 48 hrs, TGI = 15.85 μM. | 24747749 | |
Leukemia cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human leukemia cells after 48 hrs, TGI = 15.85 μM. | 22283430 | |
renal cancer cells | Growth inhibition assay | 48 hrs | Growth inhibition of human renal cancer cells after 48 hrs, TGI = 19.95 μM. | 20684599 | |
ovarian cancer cells | Growth inhibition assay | 48 hrs | Growth inhibition of human Ovarian cancer cells after 48 hrs, TGI = 19.95 μM. | 20684599 | |
renal cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human renal cancer cells after 48 hrs, TGI = 19.95 μM. | 24747749 | |
ovarian cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human ovarian cancer cells after 48 hrs, TGI = 19.95 μM. | 24747749 | |
renal cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human renal cancer cells after 48 hrs, TGI = 19.95 μM. | 22283430 | |
ovarian cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human ovarian cancer cells after 48 hrs, TGI = 19.95 μM. | 22283430 | |
ovarian cancer cells | Antitumor assay | 48 hrs | Antitumor activity against human ovarian cancer cells after 48 hrs by SRB assay, TGI = 19.9526 μM. | 19006285 | |
renal cancer cells | Antitumor assay | 48 hrs | Antitumor activity against human renal cancer cells after 48 hrs by SRB assay, TGI = 19.9526 μM. | 19006285 | |
PC3 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay, IC50 = 28.11 μM. | 29174816 | |
HEK293/MRP1 | Growth Inhibition Assay | IC50=0.055±0.0120 μM | 24284783 | ||
HEK293/pcDNA3.1 | Growth Inhibition Assay | IC50=0.004±0.0003 μM | 24284783 | ||
MCF-7 | Growth Inhibition Assay | IC50=0.0159±0.0062 μM | 24704556 | ||
MCF-7/ADR | Growth Inhibition Assay | IC50=4.4826±0.2070 μM | 24704556 | ||
HepG2 | Growth Inhibition Assay | IC50=0.0115±0.0017 μM | 24704556 | ||
HepG2/ADM | Growth Inhibition Assay | IC50=2.7863±0.2371 μM | 24704556 | ||
HEK293/ABCC1 | Growth Inhibition Assay | IC50=19.29 ± 2.08 nM | 24726739 | ||
HEK293/pcDNA3.1 | Growth Inhibition Assay | IC50=1.45 ± 0.20 nM | 24726739 | ||
SW620/AD300 | Growth Inhibition Assay | IC50=909.60 ± 8.91 nM | 24726739 | ||
SW620 | Growth Inhibition Assay | IC50=7.80 ± 0.08 nM | 24726739 | ||
MCF-7-R | Cytotoxicity Assay | IC50=5.539 ± 0.144 nM | 24858827 | ||
A549-R | Cytotoxicity Assay | IC50=12.178 ± 0.333 nM | 24858827 | ||
MCF-7-R | Growth Inhibition Assay | IC50=5.539 ± 0.144 nM | 24858827 | ||
MCF-7-WT | Growth Inhibition Assay | IC50=17.752 ± 0.218 nM | 24858827 | ||
A549-R | Growth Inhibition Assay | IC50=12.178 ± 0.333 nM | 24858827 | ||
A549-WT | Growth Inhibition Assay | IC50=19.437 ± 0.594 nM | 24858827 | ||
SHSY5Y | Growth Inhibition Assay | IC50=8.2±0.6 nM | 24921920 | ||
LAN1 | Growth Inhibition Assay | IC50=2.3±0.2 nM | 24921920 | ||
SKNAS | Growth Inhibition Assay | IC50=1.5±0.2 nM | 24921920 | ||
IGNR91 | Growth Inhibition Assay | IC50=24.3±1.7 nM | 24921920 | ||
SKNBe2C | Growth Inhibition Assay | IC50=32.8±4.0 nM | 24921920 | ||
HCT-116 | Growth Inhibition Assay | GI50=5 nM | 24927857 | ||
KBv200 (ABCB1) | Growth Inhibition Assay | IC50=0.3462 ± 0.0066 μM | 25058526 | ||
KB | Growth Inhibition Assay | IC50=0.0049 ± 0.0001 μM | 25058526 | ||
H157 | Growth Inhibition Assay | IC50=1.03 ± 0.04 miu2M | 25257911 | ||
W1 | Growth Inhibition Assay | IC50=0.0032 μM | 24140176 | ||
W1VR | Growth Inhibition Assay | IC50=0.056 μM | 24140176 | ||
K562 | Growth Inhibition Assay | IC50=0.032 ± 0.001 μM | 24135937 | ||
K562/ADR | Growth Inhibition Assay | IC50=3.261 ± 0.412 μM | 24135937 | ||
A549 | Growth Inhibition Assay | IC50=0.10 ± 0.03 μM | 23971075 | ||
A2780 | Growth Inhibition Assay | IC50=3.5 mM | 23829203 | ||
ACHN | Growth Inhibition Assay | IC50<0.1 mM | 23829203 | ||
U-937 | Growth Inhibition Assay | IC50<34 nM | 23829203 | ||
Hep-2 | Growth Inhibition Assay | IC50=0.04±0.01 μM | 23780424 | ||
Hep-2/v | Growth Inhibition Assay | IC50=1.8±0.20 μM | 23780424 | ||
SGC-7901 | Apoptosis Assay | induces apoptosis significantly | 23743572 | ||
SGC-7901/VCR | Apoptosis Assay | induces apoptosis significantly | 23743572 | ||
KB-3-1 | Growth Inhibition Assay | IC50=1.66 ± 0.162 μM | 23673445 | ||
KB-C2 | Growth Inhibition Assay | IC50=202.56 ± 42.481 μM | 23673445 | ||
KB-3-1 | Growth Inhibition Assay | IC50=1.26 ± 0.027 μM | 23673445 | ||
KB-V1 | Growth Inhibition Assay | IC50=208.85 ± 20.4 μM | 23673445 | ||
HEK293/pcDNA3.1 | Growth Inhibition Assay | IC50=24.1 ± 0.204 μM | 23673445 | ||
HEK293/ABCB1 | Growth Inhibition Assay | IC50=3512.8 ± 378.391 μM | 23673445 | ||
SGC7901 | Growth Inhibition Assay | IC50=1.26?±?0.11 μg/ml | 23564482 | ||
SGC7901/LV-NC | Growth Inhibition Assay | IC50=1.77?±?0.16 μg/ml | 23564482 | ||
SGC7901/LV-SGO1 | Growth Inhibition Assay | IC50=4.36?±?0.37 μg/ml | 23564482 | ||
SGC7901/VCR | Growth Inhibition Assay | IC53=20.53?±?1.96 μg/ml | 23564482 | ||
SGC7901/VCR-NC | Growth Inhibition Assay | IC50=19.86?±?2.01 μg/ml | 23564482 | ||
SGC7901/VCR-si-SGO1 | Growth Inhibition Assay | IC50=6.18?±?1.03 μg/ml | 23564482 | ||
SGC7901/ADR | Growth Inhibition Assay | IC50=7.85?±?0.64 μg/ml | 23564482 | ||
SGC7901/ADR-NC | Growth Inhibition Assay | IC50=8.93?±?0.68 μg/ml | 23564482 | ||
SGC7901/ADR-si-SGO1 | Growth Inhibition Assay | IC50=3.46?±?0.29 μg/ml | 23564482 | ||
Colon cancer cells | Cytotoxicity assay | Cytotoxicity against human colon cancer cells, GI50 = 0.1 μM. | 18598018 | ||
Leukemia cells | Cytotoxicity assay | Cytotoxicity against human leukemia cells, GI50 = 0.1 μM. | 18598018 | ||
Leukemia cells | Antitumor assay | Antitumor activity against leukemia cells, GI50 = 0.1 μM. | 17559205 | ||
Colon cancer cells | Antitumor assay | Antitumor activity against colon tumor cells, GI50 = 0.1 μM. | 17559205 | ||
central nervous system cancer cells | Cytotoxicity assay | Cytotoxicity against human central nervous system cancer cells, GI50 = 0.12589 μM. | 18598018 | ||
prostate cancer cells | Cytotoxicity assay | Cytotoxicity against human prostate cancer cells, GI50 = 0.12589 μM. | 18598018 | ||
CNS | Antitumor assay | Antitumor activity against CNS tumor cells, GI50 = 0.12589 μM. | 17559205 | ||
prostate cancer cells | Antitumor assay | Antitumor activity against prostate tumor cells, GI50 = 0.12589 μM. | 17559205 | ||
Melanoma cells | Cytotoxicity assay | Cytotoxicity against human melanoma cells, GI50 = 0.15849 μM. | 18598018 | ||
Melanoma cells | Antitumor assay | Antitumor activity against melanoma cells, GI50 = 0.15849 μM. | 17559205 | ||
Melanoma cells | Growth inhibition assay | Growth inhibition of human melanoma cells after 48 hrs, GI50 = 0.16 μM. | 20684599 | ||
NSCLC | Antitumor assay | Antitumor activity against NSCLC cells, GI50 = 0.25119 μM. | 17559205 | ||
Non-small cell lung carcinoma cells | Cytotoxicity assay | Cytotoxicity against human Non-small cell lung carcinoma cells, GI50 = 0.25119 μM. | 18598018 | ||
ovarian cancer cells | Cytotoxicity assay | Cytotoxicity against human ovarian cancer cells, GI50 = 0.31623 μM. | 18598018 | ||
renal cancer cells | Cytotoxicity assay | Cytotoxicity against human renal cancer cells, GI50 = 0.31623 μM. | 18598018 | ||
breast cancer cells | Cytotoxicity assay | Cytotoxicity against human breast cancer cells, GI50 = 0.31623 μM. | 18598018 | ||
renal cancer cells | Antitumor assay | Antitumor activity against renal tumor cells, GI50 = 0.31623 μM. | 17559205 | ||
ovarian cancer cells | Antitumor assay | Antitumor activity against ovarian tumor cells, GI50 = 0.31623 μM. | 17559205 | ||
breast cancer cells | Antitumor assay | Antitumor activity against breast tumor cells, GI50 = 0.31623 μM. | 17559205 | ||
COLON | Cytotoxicity assay | Cytotoxicity against human colon cancer cells, TGI = 3.98107 μM. | 18598018 | ||
COLON | Antitumor assay | Antitumor activity against colon tumor cells, TGI = 3.98107 μM. | 17559205 | ||
central nervous system cancer cells | Cytotoxicity assay | Cytotoxicity against human central nervous system cancer cells, TGI = 6.30957 μM. | 18598018 | ||
prostate cancer cells | Cytotoxicity assay | Cytotoxicity against human prostate cancer cells, TGI = 6.30957 μM. | 18598018 | ||
CNS | Antitumor assay | Antitumor activity against CNS tumor cells, TGI = 6.30957 μM. | 17559205 | ||
prostate cancer cells | Antitumor assay | Antitumor activity against prostate tumor cells, TGI = 6.30957 μM. | 17559205 | ||
Melanoma cells | Cytotoxicity assay | Cytotoxicity against human melanoma cells, TGI = 7.94328 μM. | 18598018 | ||
breast cancer cells | Cytotoxicity assay | Cytotoxicity against human breast cancer cells, TGI = 7.94328 μM. | 18598018 | ||
Melanoma cells | Antitumor assay | Antitumor activity against melanoma cells, TGI = 7.94328 μM. | 17559205 | ||
breast tumor cells | Antitumor assay | Antitumor activity against breast tumor cells, TGI = 7.94328 μM. | 17559205 | ||
NSCLC | Antitumor assay | Antitumor activity against NSCLC cells, TGI = 15.8489 μM. | 17559205 | ||
Non-small cell lung carcinoma cells | Cytotoxicity assay | Cytotoxicity against human Non-small cell lung carcinoma cells, TGI = 15.8489 μM. | 18598018 | ||
Leukemia cells | Cytotoxicity assay | Cytotoxicity against human leukemia cells, TGI = 15.8489 μM. | 18598018 | ||
Leukemia cells | Antitumor assay | Antitumor activity against leukemia cells, TGI = 15.8489 μM. | 17559205 | ||
ovarian cancer cells | Cytotoxicity assay | Cytotoxicity against human ovarian cancer cells, TGI = 19.9526 μM. | 18598018 | ||
renal cancer cells | Cytotoxicity assay | Cytotoxicity against human renal cancer cells, TGI = 19.9526 μM. | 18598018 | ||
renal tumor cells | Antitumor assay | Antitumor activity against renal tumor cells, TGI = 19.9526 μM. | 17559205 | ||
ovarian tumor cells | Antitumor assay | Antitumor activity against ovarian tumor cells, TGI = 19.9526 μM. | 17559205 | ||
neural precursor cells | Function assay | Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay | 17417631 | ||
點擊查看更多細胞系數(shù)據(jù) |
產(chǎn)品描述 | Vincristine sulfate通過與微管蛋白結合而抑制微管聚合,IC50為32 μM。Vincristine sulfate可誘導凋亡。 | ||
---|---|---|---|
靶點 |
|
體外研究(In Vitro) | ||||
體外研究活性 | Vincristine抑制微管蛋白二聚體聚合亞單位,抑制它們的聚合作用,Ki為85 nM。[1]在低濃度時,Vincristine抑制紡錘體,使染色體分離失敗,進而導致中期停滯,并抑制有絲分裂。在較高濃度時,Vincristine可能干擾且誘導全部微管解聚。[2] Vincristine 誘導腫瘤細胞凋亡,且抑制SH-SY5Y細胞增殖,IC50為0.1 μM。Vincristine誘導有絲分裂停滯,促進caspase-3和-9及cyclin B的表達,但降低cyclin D的表達。[3] Vincristine通過干擾微管功能而誘導神經(jīng)毒性形成,這會導致軸突運輸堵塞,從而導致軸突變性。[4] | |||
---|---|---|---|---|
細胞實驗 | 細胞系 | B16 黑色素瘤細胞 | ||
濃度 | 10 nM | |||
孵育時間 | 3 天 | |||
方法 | 細胞按5 × 104 cells/mL的濃度接種在含2 mL培養(yǎng)基的35-mm 實驗板上,在37°C下 含5% CO2 和95% 空氣 的環(huán)境下生長24小時。然后使用有或無10 nM藥物的新鮮培養(yǎng)基更換原來的培養(yǎng)基,繼續(xù)增殖3天。使用胰蛋白酶和EDTA將細胞分離后,每天使用庫氏計數(shù)器完成細胞計數(shù) | |||
實驗圖片 | 檢測方法 | 檢測指標 | 實驗圖片 | PMID |
Western blot | MPM2 / Cyclin B1 / Cdc25c / p-Cdc2 / Cdc2 / Aurora B / p-H3 / p-PLK1 | 26156322 | ||
Growth inhibition assay | Cell viability | 26156322 |
體內(nèi)研究(In Vivo) | ||
體內(nèi)研究活性 | Vincristine 按3 mg/kg劑量單獨腹腔注射給藥攜帶雙側皮下移植瘤RH12或RH18的小鼠,平均生長延遲120天和52天以上,且再植指數(shù)分別為0.06%和5%。[5] Vincristine 處理小鼠,通過宿主細胞介導的血管效應及直接的微管蛋白介導的的細胞毒性作用而對皮下結腸38腫瘤起作用。Vincristine (5 mg/kg) 降低腫瘤血流量,降低近75%。[6] | |
---|---|---|
動物實驗 | Animal Models | 攜帶人類橫紋肌肉瘤移植瘤Rh12的鼠 |
Dosages | 3 mg/kg | |
Administration | 腹腔注射 |
NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
---|---|---|---|---|---|
NCT05844670 | Recruiting | Pediatric Cancer |
Moi University|Princess Maxima Center for Pediatric Oncology|Amsterdam UMC location VUmc |
April 20 2023 | Phase 4 |
NCT04448834 | Withdrawn | B-cell Acute Lymphoblastic Leukemia |
Dorothy Sipkins MD PhD|Amgen|Acrotech Biopharma Inc.|Duke University |
January 2022 | Phase 2 |
分子量 | 923.04 | 分子式 | C46H58N4O14S |
CAS號 | 2068-78-2 | SDF | Download Vincristine sulfate SDF |
Smiles | CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O | ||
儲存條件(自收到貨起) | |||
體外溶解度 |
DMSO : 100 mg/mL ( (108.33 mM) ;DMSO吸濕會降低化合物溶解度,請使用新開封DMSO) Water : 100 mg/mL (108.33 mM) Ethanol : Insoluble |
摩爾濃度計算器 |
體內(nèi)溶解度 現(xiàn)配現(xiàn)用,請按從左到右的順序依次添加,澄清后再加入下一溶劑 |
動物體內(nèi)配方計算器 |
動物體內(nèi)配方計算器(澄清溶液)
第一步:請輸入基本實驗信息(考慮到實驗過程中的損耗,建議多配一只動物的藥量)
第二步:請輸入動物體內(nèi)配方組成(配方適用于不溶于水的藥物;不同批次藥物配方比例不同,請聯(lián)系Selleck為您提供正確的澄清溶液配方)
計算結果:
工作液濃度: mg/ml;
DMSO母液配制方法: mg 藥物溶于μL DMSO溶液(母液濃度mg/mL,注:如該濃度超過該批次藥物DMSO溶解度,請先聯(lián)系Selleck);
體內(nèi)配方配制方法:取μL DMSO母液,加入μL PEG300,混勻澄清后加入μL Tween 80,混勻澄清后加入μL ddH2O,混勻澄清。
體內(nèi)配方配制方法:取μL DMSO母液,加入μL Corn oil,混勻澄清。
注意:1. 首先保證母液是澄清的;
2.一定要按照順序依次將溶劑加入,進行下一步操作之前必須保證上一步操作得到的是澄清的溶液,可采用渦旋、超聲或水浴加熱等物理方法助溶。
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段,您遇到的任何問題,均可以通過撥打我們的熱線電話400-668-6834,或者技術支持郵箱tech@selleck.cn,直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。
如果有其他問題,請給我們留言。
* 必填項
問題 1:
I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?
回答:
According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.